<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Beschorner U</submitter><funding>University Medical Center Freiburg</funding><pagination>5732</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11477182</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(19)</volume><pubmed_abstract>&lt;b>Objectives&lt;/b>: To evaluate the safety and efficacy of catheter-directed thrombolysis (CDT) with the recombinant tissue plasminogen activator (rt-PA) in all patients with symptomatic peripheral artery disease in real world practice. &lt;b>Methods:&lt;/b> Consecutive patients treated with CDT between January 2013 and December 2020 were included in this retrospective analysis. The primary endpoint was the rate of serious adverse events (SAEs) until discharge. Secondary endpoints included interventional success, predictors for SAEs, bleeding and reperfusion edema/compartment syndrome, limb salvage, and clinical outcomes including target lesion revascularization rate (TLR). &lt;b>Results:&lt;/b> Overall, 1238 patients were treated with CDT. SAEs occurred in 511 (41.3%) of the patients, 314 (25.4%) bein</pubmed_abstract><journal>Journal of clinical medicine</journal><pubmed_title>Catheter-Directed Thrombolysis in the Management of Thrombotic Peripheral Artery Occlusions-Acute and Mid-Term Clinical Outcomes.</pubmed_title><pmcid>PMC11477182</pmcid><funding_grant_id>UNK</funding_grant_id><pubmed_authors>Mashayekhi K</pubmed_authors><pubmed_authors>Zeller T</pubmed_authors><pubmed_authors>Salm J</pubmed_authors><pubmed_authors>Westermann D</pubmed_authors><pubmed_authors>Beschorner U</pubmed_authors><pubmed_authors>Boehme T</pubmed_authors><pubmed_authors>Noory E</pubmed_authors><pubmed_authors>Bollenbacher R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Catheter-Directed Thrombolysis in the Management of Thrombotic Peripheral Artery Occlusions-Acute and Mid-Term Clinical Outcomes.</name><description>&lt;b>Objectives&lt;/b>: To evaluate the safety and efficacy of catheter-directed thrombolysis (CDT) with the recombinant tissue plasminogen activator (rt-PA) in all patients with symptomatic peripheral artery disease in real world practice. &lt;b>Methods:&lt;/b> Consecutive patients treated with CDT between January 2013 and December 2020 were included in this retrospective analysis. The primary endpoint was the rate of serious adverse events (SAEs) until discharge. Secondary endpoints included interventional success, predictors for SAEs, bleeding and reperfusion edema/compartment syndrome, limb salvage, and clinical outcomes including target lesion revascularization rate (TLR). &lt;b>Results:&lt;/b> Overall, 1238 patients were treated with CDT. SAEs occurred in 511 (41.3%) of the patients, 314 (25.4%) bein</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2025-04-04T01:37:08.157Z</modification><creation>2025-04-04T01:37:08.157Z</creation></dates><accession>S-EPMC11477182</accession><cross_references><pubmed>39407791</pubmed><doi>10.3390/jcm13195732</doi></cross_references></HashMap>